AIM: The aim was to evaluate tetraiodothyroacetic acid (tetrac), a thyroid hormone analog of L-thyroxin, conjugated to poly(lactic-co-glycolic acid) nanoparticles (T-PLGA-NPs) both in vitro and in vivo for the treatment of drug-resistant breast cancer. MATERIALS & METHODS: The uptake of tetrac and T-PLGA-NPs in doxorubicin-resistant MCF7 (MCF7-Dx) cells was evaluated using confocal microscopy. Cell proliferation assays and a chick chorioallantoic membrane model of FGF2-induced angiogenesis were used to evaluate the anticancer effects of T-PLGA-NPs. In vivo efficacy was examined in a MCF7-Dx orthotopic tumor BALBc nude mouse model. RESULTS: T-PLGA-NPs were restricted from entering into the cell nucleus, and T-PLGA-NPs inhibited angiogenesis by 100% compared with 60% by free tetrac. T-PLGA-NPs enhanced inhibition of tumor-cell proliferation at a low-dose equivalent of free tetrac. In vivo treatment with either tetrac or T-PLGA-NPs resulted in a three- to five-fold inhibition of tumor weight. CONCLUSION: T-PLGA-NPs have high potential as anticancer agents, with possible applications in the treatment of drug-resistant cancer.
AIM: The aim was to evaluate tetraiodothyroacetic acid (tetrac), a thyroid hormone analog of L-thyroxin, conjugated to poly(lactic-co-glycolic acid) nanoparticles (T-PLGA-NPs) both in vitro and in vivo for the treatment of drug-resistant breast cancer. MATERIALS & METHODS: The uptake of tetrac and T-PLGA-NPs in doxorubicin-resistant MCF7 (MCF7-Dx) cells was evaluated using confocal microscopy. Cell proliferation assays and a chick chorioallantoic membrane model of FGF2-induced angiogenesis were used to evaluate the anticancer effects of T-PLGA-NPs. In vivo efficacy was examined in a MCF7-Dx orthotopic tumor BALBc nude mouse model. RESULTS: T-PLGA-NPs were restricted from entering into the cell nucleus, and T-PLGA-NPs inhibited angiogenesis by 100% compared with 60% by free tetrac. T-PLGA-NPs enhanced inhibition of tumor-cell proliferation at a low-dose equivalent of free tetrac. In vivo treatment with either tetrac or T-PLGA-NPs resulted in a three- to five-fold inhibition of tumor weight. CONCLUSION: T-PLGA-NPs have high potential as anticancer agents, with possible applications in the treatment of drug-resistant cancer.
Authors: Paul J Davis; Faith B Davis; Shaker A Mousa; Mary K Luidens; Hung-Yun Lin Journal: Annu Rev Pharmacol Toxicol Date: 2011 Impact factor: 13.820
Authors: M Yalcin; E Dyskin; L Lansing; D J Bharali; S S Mousa; A Bridoux; A H Hercbergs; H Y Lin; F B Davis; G V Glinsky; A Glinskii; J Ma; P J Davis; S A Mousa Journal: J Clin Endocrinol Metab Date: 2010-02-04 Impact factor: 5.958
Authors: Shaker A Mousa; Joel J Bergh; Emie Dier; Abdelhadi Rebbaa; Laura J O'Connor; Murat Yalcin; Ahmad Aljada; Evgeny Dyskin; Faith B Davis; Hung-Yung Lin; Paul J Davis Journal: Angiogenesis Date: 2007-12-13 Impact factor: 9.596
Authors: Hung-Yun Lin; Heng-Yuan Tang; Ai Shih; Travis Keating; Gary Cao; Paul J Davis; Faith B Davis Journal: Steroids Date: 2006-12-15 Impact factor: 2.760
Authors: Amit B Shirode; Dhruba J Bharali; Sameera Nallanthighal; Justin K Coon; Shaker A Mousa; Ramune Reliene Journal: Int J Nanomedicine Date: 2015-01-09
Authors: Mathangi Srinivasan; Dhruba J Bharali; Thangirala Sudha; Maha Khedr; Ian Guest; Stewart Sell; Gennadi V Glinsky; Shaker A Mousa Journal: Oncotarget Date: 2017-06-13
Authors: Shaker A Mousa; Aleck Hercbergs; Hung-Yun Lin; Kelly A Keating; Paul J Davis Journal: Front Endocrinol (Lausanne) Date: 2021-06-21 Impact factor: 5.555